Relapsed Acute Lymphoblastic Leukemia

5Citations
Citations of this article
80Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Outcomes for children with acute lymphoblastic leukemia (ALL) have improved worldwide to >85%. For those who relapse, outcomes have remained static at ~50% making relapsed acute lymphoblastic leukemia one of the leading causes of death in childhood cancers. Those relapsing within 18 mo in the bone marrow have a particularly dismal outcome. The mainstay of treatment is chemotherapy, local radiotherapy with or without hematopoietic stem cell transplantation (HSCT). Improved biological understanding of mechanisms of relapse and drug resistance, use of innovative strategies to identify the most effective and least toxic treatment regimens and global partnerships are needed to improve outcomes in these patients. Over the last decade, new therapeutic options and strategies have been developed for relapsed ALL including immunotherapies and cellular therapies. It is imperative to understand how and when to use these newer approaches in relapsed ALL. Increasingly, integrated precision oncology strategies are being used to individualize treatment of patients with relapsed ALL, especially in patients with poor response disease.

Cite

CITATION STYLE

APA

Sidhu, J., Gogoi, M. P., Krishnan, S., & Saha, V. (2024, February 1). Relapsed Acute Lymphoblastic Leukemia. Indian Journal of Pediatrics. Springer. https://doi.org/10.1007/s12098-023-04635-4

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free